Latest News for MKGAF
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Risk and Volatility Virpax Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Merck KGaA has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Insider and Institutional Ownership 32.2% of Virpax Pharmaceuticals shares are held
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AEON Biopharma (NASDAQ: AEON - Get Free Report) and Merck KGaA (OTCMKTS:MKGAF - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Profitability This table compares AEON Biopharma and Merck
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for MKGAF.
Senate Trading
No Senate trades found for MKGAF.
U.S. House Trading
No House trades found for MKGAF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.